Pretomanid
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Treatment of adults with pulmonary extensively drug-resistant (XDR) TB and treatment-intolerant or nonresponsive multidrug-resistant (MDR) TB in a combination regimen with bedaquiline and linezolid.
- Limitations of Use: Pretomanid is not indicated for patients with drug-sensitive TB, latent TB, extra-pulmonary infection due to M. tuberculosis, MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy
- Safety and effectiveness have not been established in combination with drugs other than bedaquiline and linezolid.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
- Treatment of adults with pulmonary extensively drug-resistant (XDR) TB and treatment-intolerant or nonresponsive multidrug-resistant (MDR) TB in a combination regimen with bedaquiline and linezolid.
- Limitations of Use: Pretomanid is not indicated for patients with drug-sensitive TB, latent TB, extra-pulmonary infection due to M. tuberculosis, MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy
- Safety and effectiveness have not been established in combination with drugs other than bedaquiline and linezolid.
There's more to see -- the rest of this entry is available only to subscribers.